It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Liquid-liquid phase separation (LLPS) facilitates the formation of membraneless organelles within cells, with implications in various biological processes and disease states. AT-rich interactive domain-containing protein 1A (ARID1A) is a chromatin remodeling factor frequently associated with cancer mutations, yet its functional mechanism remains largely unknown. Here, we find that ARID1A harbors a prion-like domain (PrLD), which facilitates the formation of liquid condensates through PrLD-mediated LLPS. The nuclear condensates formed by ARID1A LLPS are significantly elevated in Ewing’s sarcoma patient specimen. Disruption of ARID1A LLPS results in diminished proliferative and invasive abilities in Ewing’s sarcoma cells. Through genome-wide chromatin structure and transcription profiling, we identify that the ARID1A condensate localizes to EWS/FLI1 target enhancers and induces long-range chromatin architectural changes by forming functional chromatin remodeling hubs at oncogenic target genes. Collectively, our findings demonstrate that ARID1A promotes oncogenic potential through PrLD-mediated LLPS, offering a potential therapeutic approach for treating Ewing’s sarcoma.
ARID1A is a chromatin remodeling protein frequently mutated in cancer. Here the authors report that ARID1A plays a role in forming membraneless organelles through liquid-liquid phase separation (LLPS). ARID1A condensates were elevated in Ewing’s sarcoma patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 Seoul National University, Creative Research Initiatives Center for Epigenetic Code and Diseases, School of Biological Sciences, Seoul, South Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
2 Korea Advanced Institute of Science & Technology, Department of Biological Sciences, Daejeon, South Korea (GRID:grid.37172.30) (ISNI:0000 0001 2292 0500)
3 Seoul National University, Interdisciplinary Program in Bioengineering, Seoul, South Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
4 Seoul National University College of Medicine, Research Center of Genomic Medicine Institute, Seoul, South Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905); Seoul National University College of Medicine, Department of Biochemistry and Molecular Biology, Seoul, South Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
5 Hopp-Children’s Cancer Center (KiTZ), Heidelberg, Germany (GRID:grid.510964.f); German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Division of Translational Pediatric Sarcoma Research, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584); National Center for Tumor Diseases (NCT), NCT Heidelberg, (A Partnership) Between DKFZ and Heidelberg University Hospital, Heidelberg, Germany (GRID:grid.461742.2) (ISNI:0000 0000 8855 0365)
6 Hopp-Children’s Cancer Center (KiTZ), Heidelberg, Germany (GRID:grid.510964.f); German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Division of Translational Pediatric Sarcoma Research, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584); National Center for Tumor Diseases (NCT), NCT Heidelberg, (A Partnership) Between DKFZ and Heidelberg University Hospital, Heidelberg, Germany (GRID:grid.461742.2) (ISNI:0000 0000 8855 0365); Heidelberg University Hospital, Institute of Pathology, Heidelberg, Germany (GRID:grid.5253.1) (ISNI:0000 0001 0328 4908)
7 Seoul National University College of Medicine, Department of Biomedical Sciences, Seoul, South Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
8 Seoul National University College of Medicine, Department of Orthopaedic Surgery, Seoul, South Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
9 Seoul National University, Interdisciplinary Program in Bioengineering, Seoul, South Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905); Seoul National University, Department of Mechanical Engineering, Seoul, South Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)